Delirium, QT-prolongation
Conditions
Keywords
QT-prolongation, Torsade de Pointes, QT-prolonging drugs
Brief summary
A prospective, observational study in a university hospital (UZ Leuven). Patients are included when they are treated with a potentional QT-prolonging drug: haloperidol for delirium, antibiotics (moxifloxacin, levofloxacin, azithromycin, clarithromycin, erythromycin, co-trimoxazole), antimycotics (ketoconazole, itraconazole, fluconazole, voriconazole), methadone, tacrolimus and oral oncolytics. An ECG is taken before the administration of the drug and 3-5 days after starting the drug to investigate the change in duration of the QTc-interval. Risk factors for developing QT-prolongation will be documented. Together with ECG2, an additional blood sample will be collected to measure the blood concentration of the drug.
Interventions
DRUGHaloperidol, azi/clari/erythromycin, levo/moxifloxacin, co-trimoxazole, vori/keto/flu/itraconazole, methadone, tacrolimus, sunitinib
Sponsors
Agentschap voor Innovatie door Wetenschap en Technologie
KU Leuven
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* treatment with a potentional QT-prolonging drug of our list * inpatient of UZ Leuven, admitted on one of the participating wards
Exclusion criteria
* \< 18 years old * DNR-code 3 * not possible to take an ECG before the start of haloperidol
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| change in QTc-interval (corrected for heart rate) | before and 3-5 days after the start of a potentional QT-prolonging drug |
Countries
Belgium
Outcome results
None listed